Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase

P A PHILLIPS, J SASADEUS,* G PHODSMAN, J HOROWITZ, A SALTUPS,* C I JOHNSTON

From the Department of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria; and the *Department of Cardiology, Prince Henry's Hospital, Melbourne, Victoria, Australia

SUMMARY Plasma concentrations of immunoreactive atrial natriuretic peptide (mean (SEM)) were measured in 135 patients admitted to two coronary care units with myocardial infarction, ischaemic chest pain, or non-ischaemic chest pain. Concentrations were significantly higher in patients with acute myocardial infarction not treated with systemic thrombolysis (60·4 (14·3) pg/ml) than in patients with non-ischaemic chest pain (21·1 (4·3) pg/ml). Patients with ischaemic chest pain had intermediate values (39·3 (7·1) pg/ml). Patients with acute myocardial infarction treated with intravenous streptokinase had normal concentrations of plasma atrial natriuretic peptide (20·2 (3·6) pg/mg), which were significantly lower than those in patients with myocardial infarction not given streptokinase. These changes could not be explained by factors such as age, pre-existing hypertension, renal dysfunction, or cardiac failure, nor treatment other than streptokinase. Raised plasma concentrations of atrial natriuretic peptide in acute myocardial infarction may be a homoeostatic response acting to reduce atrial pressures by natriuresis, diuresis, and venodilatation. The lower concentrations of atrial natriuretic peptide in patients with acute myocardial infarction treated with streptokinase may reflect a short term beneficial haemodynamic effect of streptokinase.

Plasma concentrations of atrial natriuretic peptide are increased by plasma volume expansion1-3 and are higher than normal in patients with congestive cardiac failure.4-10 This increase is probably a response to atrial distension and is probably a homoeostatic mechanism to lower atrial pressures through natriuresis, diuresis, and venodilatation.4,11 Most studies of plasma atrial natriuretic peptide concentrations in human ventricular dysfunction have been performed in patients with chronic heart disease and overt fluid retention. We measured plasma concentrations of atrial natriuretic peptide in patients without a past history of cardiac failure when infarction was essentially complete but before appreciable volume expansion could occur. We wanted to find out whether plasma concentrations of atrial natriuretic peptide rise in response to acute left ventricular muscle dysfunction without volume expansion. We also aimed to assess the effect on plasma concentrations of atrial natriuretic peptide of myocardial salvage by intravenous streptokinase.

Patients and methods

Blood samples were obtained from 196 consecutive fasting patients with chest pain admitted to the coronary care units of two university teaching hospitals. Blood was drawn at 0730 on the morning after admission before the patient got up. Patients with significantly impaired renal function (assessed by plasma concentrations of creatinine > 150 µmol/l) or with a past history of cardiac failure were excluded (26 patients) because plasma atrial natriuretic peptide is known to be raised in these conditions.5-10 12-15 Drug treatment, including intravenous streptokinase for evolving transmural myocardial infarction (1·5 million units within four hours of the onset of chest pain) was given as required. Patients were classified as having an acute myocardial infarction if they had all of: a compatible history, appropriate electrocardiographic changes, and peak plasma concentrations of creatine kinase or creatine kinase MB isoenzyme.
greater than or equal to twice the upper limit of normal (upper limits of normal: creatine kinase 160 IU/l (2.66 µkat/l) creatine kinase MB isoenzyme 22 IU/l (0.22 µkat/l)). The infarct site was classified as anterior or inferior. Patients were considered to have ischaemic chest pain if they had anginal pain but no enzyme rise or subsequent permanent electrocardiographic changes. Patients were classified as having non-ischaemic chest pain if an alternative diagnosis was established or if after subsequent extensive investigation (for example coronary angiography) no evidence for acute myocardial ischaemia could be found. Thirty five patients who did not fulfil these classification criteria were excluded. Cardiac failure was graded as Killip class I–IV. The approval of the ethics committee was obtained before the study.

**Radioimmunoassay for Atrial Natriuretic Peptide**

Blood (10 ml) was taken into chilled tubes containing edetic acid (0.15 nmol) and 500 kallikrein inhibitor units of aprotinin (Trasylol, Bayer), placed on ice, centrifuged at 4°C, and the plasma was stored at −20°C until radioimmunoassay. The inter-assay and intra-assay coefficients of variation are 12.4% and 6.4% respectively. The normal range is 10–40 pg/ml with a lower limit of detection of 4 pg/ml.

**Statistical Analysis**

Plasma concentrations of atrial natriuretic peptide were log transformed because the results were not normally distributed. We used analyses of variance and covariance, correlations, and unpaired t tests on continuous variables, and χ² tests on categorical variables. If a significant main effect was found by analysis of variance we measured individual differences between means by the Newman–Keuls retrospective comparisons test. Data for continuous variables are presented as means (SEM).

**Results**

The table shows details of the patients. The distribution of sex, systolic and diastolic blood pressure, pulse rate, or past history of hypertension was similar in all the groups. The plasma concentration of creatinine was significantly higher in patients with acute myocardial infarction treated with streptokinase than in patients with non-ischaemic chest pain (p < 0.01). Past myocardial infarction was more common in those with ischaemic chest pain (p < 0.001). Past myocardial infarction was more common in those with ischaemic chest pain (p < 0.001).

Plasma concentrations of atrial natriuretic peptide were significantly higher (p < 0.01) in those with acute myocardial infarction not treated with streptokinase (60.4 (14.3) pg/ml) than in those with non-ischaemic chest pain (21.1 (4.3) pg/ml) but not different from those in patients with ischaemic chest pain (39.3 (7.1) pg/ml). The most striking finding, however, was the normal plasma concentration of atrial natriuretic peptide in patients with acute myocardial infarction treated with streptokinase (20.1 (3.6) pg/ml). This was significantly lower (p < 0.01) than that in patients with acute myocardial infarction not treated with streptokinase. These differences were not explained by the lower age of the patients with acute myocardial infarction treated with streptokinase and those with non-ischaemic chest pain compared with the other two groups (p < 0.05), because analysis of covariance of the data on plasma concentrations of atrial natriuretic peptide with age as covariate showed the same differences (p < 0.001). Nor was this difference caused by differences in treatment (intravenous fluids, long acting nitrates, β blockers, calcium antagonists, angiotensin converting enzyme inhibitors, vasodilators, digoxin, inotropes, atropine) before blood sampling as usage of these drugs was similar in each group. Opiates were used more frequently in those with acute myocardial infarction treated with streptokinase, and less often in patients with ischaemic chest pain (p < 0.001). Opiates were usually administered before admission to the coronary care unit, 8–32 hours before blood sampling for estimation of plasma concentrations of atrial natriuretic peptide. Treatment with diuretics (mostly as part of a regular regimen for hypertension) was more common in patients with ischaemic chest pain (p < 0.05).

**Table Clinical details (mean (SEM) or %) of the patients studied**

<table>
<thead>
<tr>
<th></th>
<th>NICP</th>
<th>ICP</th>
<th>AMI no SK</th>
<th>AMI SK</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of patients</td>
<td>18</td>
<td>52</td>
<td>43</td>
<td>22</td>
</tr>
<tr>
<td>Women (%)</td>
<td>8 (44)</td>
<td>24 (46)</td>
<td>10 (23)</td>
<td>5 (23)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>10 (56)</td>
<td>28 (54)</td>
<td>33 (77)</td>
<td>17 (77)</td>
</tr>
<tr>
<td>Plasma creatinine (µmol/l)</td>
<td>52 (2)</td>
<td>62 (1)</td>
<td>61 (2)</td>
<td>54 (2)</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>81 (3)</td>
<td>88 (2)</td>
<td>91 (3)</td>
<td>97 (4)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>126 (2)</td>
<td>125 (2)</td>
<td>121 (2)</td>
<td>121 (4)</td>
</tr>
<tr>
<td>Pulse rate (beats/min)</td>
<td>75 (2)</td>
<td>73 (2)</td>
<td>72 (2)</td>
<td>76 (3)</td>
</tr>
<tr>
<td>No with past hypertension (%)</td>
<td>11 (61)</td>
<td>27 (52)</td>
<td>17 (40)</td>
<td>11 (50)</td>
</tr>
<tr>
<td>No with past myocardial infarction (%)</td>
<td>3 (17)</td>
<td>34 (65)</td>
<td>6 (14)</td>
<td>4 (18)</td>
</tr>
<tr>
<td>No in Killip class I (%)</td>
<td>17 (94)</td>
<td>46 (89)</td>
<td>29 (67)</td>
<td>18 (82)</td>
</tr>
<tr>
<td>No in Killip class &gt;1 (%)</td>
<td>1 (6)</td>
<td>6 (11)</td>
<td>14 (33)</td>
<td>4 (18)</td>
</tr>
</tbody>
</table>

AMI, acute myocardial infarction; ICP, ischaemic chest pain; NICP, non-ischaemic chest pain; SK, streptokinase.
Atrial natriuretic peptide in acute myocardial infarction

There was an excess of patients with signs of cardiac failure (Killip class > I) in patients with acute myocardial infarction not treated with streptokinase (p < 0.05). Overall, plasma concentrations of atrial natriuretic peptide were higher (p < 0.01) in patients in Killip class II (65.7 (15.7) pg/ml, n = 24) than in those in Killip class I (33.9 (5.6) pg/ml, n = 110). There was only one patient in Killip class III and his plasma concentration of atrial natriuretic peptide was 158.8 pg/ml. Patients with existing cardiac failure were excluded at the start of the trial.

There was a significant correlation between plasma atrial natriuretic peptide and age (r = 0.37, p < 0.001) but no significant correlation with plasma creatinine, probably because patients with significantly impaired renal function had been excluded. There was no significant correlation between plasma atrial natriuretic peptide and peak concentrations of cardiac enzymes.

Although plasma concentrations of atrial natriuretic peptide were slightly higher in patients with inferior infarcts (56.2 (17.3) pg/ml, n = 34) than in those with anterior infarcts (36.4 (8.0) pg/ml, n = 31) this difference was not statistically significant. Similarly, there was no difference in plasma concentrations of atrial natriuretic peptide between transmural and non-transmural acute myocardial infarction.

Discussion

Atrial distension is probably the main stimulus to secretion of atrial natriuretic peptide. In patients with chronic congestive cardiac failure ventricular dysfunction and fluid retention coexist and lead to increased atrial pressures and raised plasma concentrations of atrial natriuretic peptide. In rats with experimental infarction plasma concentrations of atrial natriuretic peptide are raised in proportion to myocardial dysfunction and infarct size without expansion of extracellular fluid volume.22 Similarly, we found raised plasma concentrations of atrial natriuretic peptide in patients during the acute stage of myocardial infarction before appreciable fluid retention could occur and lead to an additional increase in atrial pressures. Thus these results suggest that acute myocardial dysfunction alone, by reducing diastolic ventricular compliance and raising atrial pressures, may increase plasma concentrations of atrial natriuretic peptide. Plasma concentrations of atrial natriuretic peptide were also higher in patients in whom signs of cardiac failure developed. This result accorded with previous findings. Since atrial natriuretic peptide causes venodilatation, natriuresis, and diuresis, raised concentrations of atrial natriuretic peptide may be beneficial in acute myocardial infarction because they will reduce cardiac preload and salt and water retention and so limit pulmonary oedema.

Plasma concentrations of atrial natriuretic peptide were reported in a study of patients with acute myocardial infarction. In that study, however, the control group was not under the same conditions of coronary care as the patients with infarcts nor were the concentrations of atrial natriuretic peptide corrected for the younger age of the controls; this may have confounded the findings of higher plasma concentrations of atrial natriuretic peptide in acute myocardial infarction.24 None the less, our study confirms and extends these findings.

Of interest was the normal mean plasma concentration of atrial natriuretic peptide in patients with acute myocardial infarction treated with streptokinase, compared with the threefold higher concentration in acute myocardial infarction patients not treated by thrombolysis. One explanation for this would be the beneficial effect of intravenous streptokinase given within four hours of the onset of chest pain in acute myocardial infarction in preserving the myocardium and myocardial function. Since plasma concentrations of atrial natriuretic peptide are raised in proportion to haemodynamic dysfunction one might expect lower plasma concentrations of atrial natriuretic peptide in patients with acute myocardial infarction treated successfully with streptokinase.

Other factors might also have a role. Streptokinase catalyses the conversion of plasminogen to the protease plasmin. It is unlikely that streptokinase led to degradation of the atrial natriuretic peptide and lower plasma concentrations of atrial natriuretic peptide because streptokinase added to the assay system for atrial natriuretic peptide assay did not affect concentrations of atrial natriuretic peptide (P A Phillips, G P Hodson, C J Johnston, unpublished observation). Streptokinase is unlikely to have had a proteolytic effect at the time of sampling because (a) streptokinase has a fibrinolytic half life of approximately 15–30 min, (b) blood samples for the measurement of plasma atrial natriuretic peptide were taken at least seven hours after streptokinase treatment, and (c) atrial natriuretic peptide has a plasma half life of 2–3 min. Another factor that might have led to lower plasma concentrations of atrial natriuretic peptide after streptokinase might be the vasodilatory effects of fibrin and fibrinogen degradation products.

A further explanation for the lower concentrations of plasma atrial natriuretic peptide in patients with acute myocardial infarction treated with streptokinase might be differing drug treatment. This too seems unlikely since opiates were the only drugs given more
often to patients who received streptokinase, and these were usually given several hours before blood sampling. Furthermore, morphine raised plasma atrial natriuretic peptide in rats and so would be unlikely to lead to the lower concentrations of atrial natriuretic peptide seen in this study. Similarly, the lower concentrations of atrial natriuretic peptide cannot be explained by the lower age of the patients treated with streptokinase, because analysis of covariance controlling for age showed that age was not a confounding factor. Nor does arrhythmia or raised blood pressure explain the differences in plasma concentrations of atrial natriuretic peptide across the groups because pulse rates and systolic and diastolic blood pressures were similar. The presence of other conditions that might influence plasma atrial natriuretic peptide (renal impairment, previous myocardial infarction) would also not explain the results. Patients with renal impairment were excluded, and those with the lowest plasma concentrations of atrial natriuretic peptide (those with acute myocardial infarction treated with streptokinase) had the highest plasma creatinine. Hypertension was equally prevalent across the groups and past myocardial infarction was more common in the group with ischaemic chest pain.

Patients with ischaemic chest pain had a mean plasma atrial natriuretic peptide concentration intermediate between that of patients with acute myocardial infarction and that of patients with non-ischaemic chest pain. This suggests that concentrations of atrial natriuretic peptide may rise in response to ventricular diastolic dysfunction secondary to myocardial ischaemia. Unfortunately because this group had a higher prevalence of previous myocardial infarction, which might raise plasma atrial natriuretic peptide, as well as diuretic therapy, which might lower plasma atrial natriuretic peptide, these results are difficult to interpret.

In summary, the results show that plasma concentrations of atrial natriuretic peptide are raised in the acute phase of myocardial infarction. This accords with the concept that myocardial dysfunction without volume overload can lead to raised atrial pressures and release of atrial natriuretic peptide. Because atrial natriuretic peptide causes natriuresis, diuresis, and venodilatation, raised concentrations of atrial natriuretic peptide might therefore be beneficial by reducing cardiac preload and limiting salt and water retention and pulmonary oedema during the acute stages of myocardial ischaemia. The mean plasma concentration of atrial natriuretic peptide was normal in patients with acute myocardial infarction treated with streptokinase. This may reflect improved haemodynamic function because of myocardial salvage with streptokinase. Further studies are needed to see if the estimation of plasma atrial natriuretic peptide in the acute phase of acute myocardial infarction is a predictor of outcome, especially after streptokinase treatment, and whether atrial natriuretic peptide analogues are likely to be useful in the management of myocardial infarction.

This study was supported by grants from the National Health and Medical Research Council and National Heart Foundation of Australia.

References

14 Ogawa K, Smith AI, Hodson GP, Jackson B, Woodcock EA, Johnston CI. Plasma atrial natriuretic peptide: concentrations and circulating forms in...
Atrial natriuretic peptide in acute myocardial infarction


Plasma atrial natriuretic peptide in patients with acute myocardial infarction: effects of streptokinase.

P A Phillips, J Sasadeus, G P Hodsman, J Horowitz, A Saltups and C I Johnston

Br Heart J 1989 61: 139-143
doi: 10.1136/hrt.61.2.139

Updated information and services can be found at:
http://heart.bmj.com/content/61/2/139

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/